Want to see GB:IXI full AI Analyst Report?
Top Page
IXICO plc
(LSE:IXI)
Select Model
Select Model
Rating:61Neutral
Price Target:
12.50 p
▲(61.29% Upside)
Action:Reiterated
Date:10/28/26
The score is driven primarily by weak underlying financial performance (ongoing losses and negative operating cash flow) offset by a constructive earnings-call backdrop (strong order book visibility, improving margins, narrowed EBITDA loss, and a materially strengthened cash position). Technicals add support via strong trend momentum but are tempered by extremely overbought readings, while valuation remains challenged due to negative earnings and no provided yield support.
Positive Factors
Revenue Growth and Order Visibility
Strong recent revenue growth combined with substantial order-book coverage improves near-term predictability and supports execution against guidance. The 1.75 book-to-bill ratio also indicates continued commercial demand, giving IXICO a stronger base from which to scale its specialist clinical-trial services.
Negative Factors
Persistent Losses
Continued EBITDA losses mean the business has not yet demonstrated self-funded profitability, despite improved operating performance. The 2029 target indicates that further investment and execution are required before earnings can become a durable source of cash, limiting financial resilience in the interim.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Order Visibility
Strong recent revenue growth combined with substantial order-book coverage improves near-term predictability and supports execution against guidance. The 1.75 book-to-bill ratio also indicates continued commercial demand, giving IXICO a stronger base from which to scale its specialist clinical-trial services.
Read all positive factors
IXICO plc (IXI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£25.73M
Dividend YieldN/A
Average Volume (3M)152.86K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth13.04%
EPS Growth15.88%
CountryUK
Employees79
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding218,974,290
10 Day Avg. Volume354,409
30 Day Avg. Volume152,862
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.01
Price to Sales (P/S)1.81
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)N/A
IXICO plc Business Overview & Revenue Model
Company Description
IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and...
How the Company Makes Money
IXICO makes money by providing contracted services to life sciences customers (such as pharmaceutical and biotechnology companies and, where applicable, clinical research organizations) involved in clinical development programs. Revenue is primari...
IXICO plc Earnings Call Summary
Earnings Call Date:May 19, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Dec 08, 2026
Earnings Call Sentiment Positive
The call conveyed solid operational progress and strong commercial momentum: double-digit revenue growth (23% in H1), a record GBP 18.1m order book providing 95% coverage of FY26 guidance, improved gross margin (53%), a narrowed EBITDA loss (GBP 0.5m), a successful GBP 10m capital raise and a strategic Medidata partnership that supports productization and scaling. Offsetting these positives are continuing near-term losses, timing risk for TechBio-derived recurring revenue due to productization and regulatory timelines, some exposure to trial descopes/cancellations and the need to convert an increasingly promising pipeline into contracted revenue in large indications like Alzheimer’s and Parkinson’s. Overall, the momentum and balance sheet reinforcement from the capital raise materially outweigh the near-term investment-driven drawbacks, but investors should note the multi-year horizon to realize TechBio recurring revenue and the stated 2029 target for sustained profitability.Positive Updates
Strong Revenue Growth
Revenue for H1 FY26 was GBP 3.9m, a 23% increase versus H1 FY25, ahead of the company's 15% full-year growth guidance.
Negative Updates
Ongoing Net Losses and Near-Term EBITDA Impact
Despite narrowed losses, the business remained EBITDA negative (GBP 0.5m loss in H1). Management expects further short-term EBITDA impact due to continued TechBio investments and has pushed sustainable profitability target to 2029.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Revenue for H1 FY26 was GBP 3.9m, a 23% increase versus H1 FY25, ahead of the company's 15% full-year growth guidance.
Read all positive updates
Company Guidance
The company reiterated full‑year revenue guidance of GBP 7.5m (15% growth target) after a strong H1: revenues of GBP 3.9m (+23% YoY), 53% gross margin and an EBITDA loss narrowed to GBP 0.5m; management said the record order book of GBP 18.1m (up 31% since year‑end and 38% vs H1 2025) provides ~95% visibility of this year’s guidance. Over the last 12 months IXICO recognized GBP 7.2m of revenue, signed GBP 12.6m of new contracts (book‑to‑bill 1.75) and now has its largest project at 19% of order book; cash at half‑year was GBP 1.7m, augmented by GBP 9.4m net raise to GBP 10.8m at end‑April, with net assets GBP 10.7m (long‑term assets ~GBP 8m, working capital ~GBP 3.3m, lease liabilities ~GBP 0.5m). Management expects sustainable profitability and positive cash flow by 2029, will keep capex at c. GBP 300k per half (plus recent ~GBP 100k IT and ~GBP 100k refurb), aims to productize 2–3 TechBio products this year and targets FDA/software‑as‑medical‑device regulatory work on a 18–24 month horizon.IXICO plc Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.28M | 6.53M | 5.77M | 6.67M | 8.64M | 9.19M |
| Gross Profit | 3.51M | 2.91M | 2.71M | 3.27M | 4.77M | 5.53M |
| EBITDA | -2.33M | -2.02M | -1.68M | -707.00K | 1.55M | 1.73M |
| Net Income | -1.82M | -1.65M | -2.00M | -1.18M | 1.03M | 1.51M |
Balance Sheet | ||||||
| Total Assets | 12.99M | 13.84M | 11.19M | 12.99M | 14.65M | 14.26M |
| Cash, Cash Equivalents and Short-Term Investments | 1.68M | 3.54M | 1.79M | 4.03M | 5.77M | 6.68M |
| Total Debt | 559.00K | 179.00K | 314.00K | 387.00K | 516.00K | 597.00K |
| Total Liabilities | 2.27M | 2.10M | 1.72M | 1.56M | 2.16M | 2.78M |
| Stockholders Equity | 10.72M | 11.74M | 9.46M | 11.43M | 12.49M | 11.48M |
Cash Flow | ||||||
| Free Cash Flow | -2.17M | -934.00K | -2.20M | -1.66M | -815.00K | -1.54M |
| Operating Cash Flow | -2.02M | -883.00K | -1.73M | 302.00K | 1.43M | 614.00K |
| Investing Cash Flow | -1.11M | -870.00K | -377.00K | -1.86M | -2.25M | -2.15M |
| Financing Cash Flow | -202.00K | 3.50M | -134.00K | -156.00K | -114.00K | 270.00K |
IXICO plc Technical Analysis
Positive
7.75
Price Trends
8.04
Positive
8.17
Positive
8.26
Positive
Market Momentum
0.96
Negative
96.08
Negative
86.36
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IXI, the sentiment is Positive. The current price of 7.75 is below the 20-day moving average (MA) of 8.79, below the 50-day MA of 8.04, and below the 200-day MA of 8.26, indicating a bullish trend. The MACD of 0.96 indicates Negative momentum. The RSI at 96.08 is Negative, neither overbought nor oversold. The STOCH value of 86.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:IXI.
IXICO plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | £25.73M | -5.99 | -16.18% | ― | 13.04% | 15.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £41.30M | -3.33 | -35.13% | 3.33% | -24.24% | -329.49% | |
43 Neutral | £296.94M | -6.69 | -1293.07% | ― | ― | ― | |
43 Neutral | £10.23M | -9.83 | -46.61% | ― | 28.35% | 57.14% | |
42 Neutral | £1.93M | -2.13 | -152.03% | ― | 20.05% | -11.11% | |
40 Underperform | £14.18M | -0.26 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:IXI
IXICO plc
11.75
0.50
4.44%
GB:AVCT
Avacta Group plc
61.00
-9.00
-12.86%
GB:OBD
Oxford BioDynamics
0.11
-0.22
-67.19%
GB:PYC
Physiomics
0.43
0.00
0.00%
GB:HVO
Open Orphan Plc
6.00
-0.58
-8.81%
GB:APTA
Aptamer Group Plc
0.30
-0.52
-64.02%
IXICO plc Corporate Events
Business Operations and StrategyFinancial Disclosures
IXICO secures £1.5m Alzheimer’s imaging and biomarker contracts after strong FY26
Positive
Oct 22, 2026
IXICO has announced two Alzheimer’s‑focused contracts worth a combined £1.5 million, underscoring the commercial traction of its IXI neuroimaging platform across a widening customer base. The deal news comes on the heels of a trad...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
IXICO beats revenue guidance as neuroimaging demand accelerates
Positive
Oct 20, 2026
IXICO plc expects revenues of £8.3 million for the year to 30 September 2026, representing 28% growth on 2025 and surpassing its recently upgraded guidance after a late surge in analysis orders. The group’s order book has risen to £...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
IXICO beats guidance with 28% revenue growth and strengthened order book
Positive
Oct 20, 2026
IXICO plc expects revenue of £8.3 million for the year to 30 September 2026, a 28% increase on 2025 and ahead of upgraded guidance, driven by a late surge in analysis orders. The neuroscience-focused imaging specialist has grown its year-end ...
Business Operations and Strategy
IXICO Showcases Neuromelanin MRI Advances for Parkinson’s Disease at European Radiology Meeting
Positive
Oct 1, 2026
IXICO plc has unveiled new research at the European Society for Magnetic Resonance in Medicine Biology conference comparing two neuromelanin-sensitive MRI techniques for visualising the substantia nigra, a key brain region in Parkinson’s di...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.